## Supplementary Table 3. Proportion of subjects with complete viral suppression at week 96-subgroup analysis – full analysis set

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Statistics** | **TMF 25 mg** | **TDF 300 mg** | **Difference (%)\*** | **95% CI\*** | ***p*-value** |
| **HBeAg-positive** | | N = 486 | N = 246 |  |  |  |
| HBV DNA at Screening | |  |  |  |  |  |
| < 8 log10 | n | 242 | 123 |  |  |  |
| IU/mL | Complete inhibition (%) | 197  (81.4) | 105  (85.4) | -4.0 | (-11.90,3.98) | 0.344 |
|  | 95% CI | (75.92,86.10) | (77.86,91.09) |  |  |  |
| ≥ 8 log10 | n | 244 | 123 |  |  |  |
| IU/mL | Complete inhibition (%) | 147 (60.2) | 72 (58.5) | 1.7 | (-8.94,12.36) | 0.753 |
|  | 95% CI | (53.81,66.43) | (49.31,67.35) |  |  |  |
| Oral Antiviral Treatment | |  |  |  |  |  |
| Treated | n | 110 | 56 |  |  |  |
|  | Complete inhibition (%) | 81 (73.6) | 42 (75.0) | -1.4 | (-15.38,12.65) | 0.850 |
|  | 95% CI | (64.38,81.58) | (61.63,85.61) |  |  |  |
| Untreated | n | 376 | 190 |  |  |  |
|  | Complete inhibition (%) | 263 (69.9) | 135 (71.1) | -1.1 | (-9.05,6.84) | 0.786 |
|  | 95% CI | (65.04,74.54) | (64.05,77.39) |  |  |  |
| Age (years) |  |  |  |  |  |  |
| < 50 | n | 454 | 218 |  |  |  |
|  | Complete inhibition (%) | 321 (70.7) | 154 (70.6) | -0.4 | (-7.48,6.73) | 0.919 |
|  | 95% CI | (66.28,74.85) | (64.11,76.60) |  |  |  |
| ≥ 50 | n | 32 | 28 |  |  |  |
|  | Complete inhibition (%) | 23 (71.9) | 23 (82.1) | -7.1 | (-27.69,  13.54) | 0.517 |
|  | 95% CI | (53.25,86.25) | (63.11,93.94) |  |  |  |
| Sex |  |  |  |  |  |  |
| Man | n | 345 | 175 |  |  |  |
|  | Complete inhibition (%) | 236 (68.4) | 123 (70.3) | -1.9 | (-9.88,6.07) | 0.645 |
|  | 95% CI | (63.21,73.28) | (62.92,76.95) |  |  |  |
| Woman | n | 141 | 71 |  |  |  |
|  | Complete inhibition (%) | 108 (76.6) | 54 (76.1) | 0.4 | (-11.62,  12.45) | 0.945 |
|  | 95% CI | (68.73,83.31) | (64.46,85.39) |  |  |  |
| HBV Genotype | |  |  |  |  |  |
| B | n | 192 | 92 |  |  |  |
|  | Complete inhibition (%) | 130 (67.7) | 64 (69.6) | -1.0 | (-12.16,  10.26) | 0.869 |
|  | 95% CI | (60.60,74.26) | (59.10,78.73) |  |  |  |
| C | n | 292 | 152 |  |  |  |
|  | Complete inhibition (%) | 213 (72.9) | 113 (74.3) | -2.0 | (-10.35,6.31) | 0.640 |
|  | 95% CI | (67.46,77.96) | (66.64,81.07) |  |  |  |
| ALT Baseline | |  |  |  |  |  |
| ˃ULN | n | 451 | 226 |  |  |  |
|  | Complete inhibition (%) | 320 (71.0) | 166 (73.5) | -2.3 | (-9.16,4.61) | 0.523 |
|  | 95% CI | (66.52,75.10) | (67.19,79.09) |  |  |  |
| ULN | n | 35 | 20 |  |  |  |
|  | Complete inhibition (%) | 24 (68.6) | 11 (55.0) | 6.8 | (-17.70,  31.22) | 0.573 |
|  | 95% CI | (50.71,83.15) | (31.53,76.94) |  |  |  |
| Treatment Compliance | |  |  |  |  |  |
| < 95% | n | 34 | 16 |  |  |  |
|  | Complete inhibition (%) | 15 (44.1) | 9 (56.3) | -15.9 | (-45.13,  13.27) | 0.319 |
|  | 95% CI | (27.19,62.11) | (29.88,80.25) |  |  |  |
| ≥ 95% | n | 452 | 230 |  |  |  |
|  | Complete inhibition (%) | 329 (72.8) | 168 (73.0) | 0.1 | (-6.68,6.94) | 0.970 |
|  | 95% CI | (68.43,76.84) | (66.82,78.66) |  |  |  |
|  |  |  |  |  |  |  |
| **HBeAg-negative** | | N = 180 | N = 90 |  |  |  |
| HBV DNA at screening | |  |  |  |  |  |
| < 8 log10 | n | 171 | 85 |  |  |  |
| IU/mL | Complete inhibition (%) | 160 (93.6) | 80 (94.1) | -0.6 | (-6.76,5.66) | 0.864 |
|  | 95% CI | (88.78,96.75) | (86.80,98.06) |  |  |  |
| ≥ 8 log10 | n | 9 | 5 |  |  |  |
| IU/mL | Complete inhibition (%) | 9 (100.0) | 4 (80.0) | 20.0 | (-15.06,  55.06) | 0.164 |
|  | 95% CI | (66.37,100.00) | (28.36,99.49) |  |  |  |
| Oral Antiviral Treatment | |  |  |  |  |  |
| Treated | n | 37 | 19 |  |  |  |
|  | Complete inhibition (%) | 35 (94.6) | 16 (84.2) | 10.4 | (-7.56,28.33) | 0.197 |
|  | 95% CI | (81.81,99.34) | (60.42,96.62) |  |  |  |
| Untreated | n | 143 | 71 |  |  |  |
|  | Complete inhibition (%) | 134 (93.7) | 68 (95.8) | -2.1 | (-8.21,4.07) | 0.536 |
|  | 95% CI | (88.39,97.08) | (88.14,99.12) |  |  |  |
| Age (year) |  |  |  |  |  |  |
| < 50 | n | 134 | 67 |  |  |  |
|  | Complete inhibition (%) | 128 (95.5) | 64 (95.5) | 0.0 | (-6.01,6.09) | 0.989 |
|  | 95% CI | (90.51,98.34) | (87.47,99.07) |  |  |  |
| ≥ 50 | n | 46 | 23 |  |  |  |
|  | Complete inhibition (%) | 41 (89.1) | 20 (87.0) | 3.1 | (-13.34,  19.51) | 0.710 |
|  | 95% CI | (76.43,96.38) | (66.41,97.22) |  |  |  |
| Sex |  |  |  |  |  |  |
| Man | n | 135 | 68 |  |  |  |
|  | Complete inhibition (%) | 127 (94.1) | 64 (94.1) | -0.3 | (-7.16,6.66) | 0.944 |
|  | 95% CI | (88.66,97.41) | (85.62,98.37) |  |  |  |
| Woman | n | 45 | 22 |  |  |  |
|  | Complete inhibition (%) | 42(93.3) | 20(90.9) | 2.0 | (-11.78,  15.82) | 0.772 |
|  | 95% CI | (81.73,98.60) | (70.84,98.88) |  |  |  |
| HBV Genotype | |  |  |  |  |  |
| B | n | 93 | 51 |  |  |  |
|  | Complete inhibition (%) | 90 (96.8) | 48 (94.1) | 1.9 | (-5.13,8.97) | 0.588 |
|  | 95% CI | (90.86,99.33) | (83.76,98.77) |  |  |  |
| C | n | 80 | 35 |  |  |  |
|  | Complete inhibition (%) | 74 (92.5) | 32 (91.4) | 0.6 | (-10.32,  11.60) | 0.909 |
|  | 95% CI | (84.39,97.20) | (76.94,98.20) |  |  |  |
| ALT Baseline | |  |  |  |  |  |
| > ULN | n | 163 | 71 |  |  |  |
|  | Complete inhibition (%) | 153 (93.9) | 65 (91.5) | 2.2 | (-5.26,9.61) | 0.550 |
|  | 95% CI | (89.01,97.02) | (82.51,96.84) |  |  |  |
| ≤ ULN | n | 17 | 19 |  |  |  |
|  | Complete inhibition (%) | 16 (94.1) | 19 (100.0) | -5.0 | (-15.45,5.45) | 0.371 |
|  | 95% CI | (71.31,99.85) | (82.35,100.00) |  |  |  |
| Treatment Compliance | |  |  |  |  |  |
| < 95% | n | 6 | 4 |  |  |  |
|  | Complete inhibition (%) | 5 (83.3) | 3 (75.0) | 0.0 | (-60.01,  60.01) | 1.000 |
|  | 95% CI | (35.88,99.58) | (19.41,99.37) |  |  |  |
| ≥ 95% | n | 174 | 86 |  |  |  |
|  | Complete inhibition (%) | 164 (94.3) | 81 (94.2) | -0.1 | (-6.10,5.90) | 0.975 |
|  | 95% CI | (89.68,97.21) | (86.95,98.09) |  |  |  |
| When the subgroup was not one of the random stratification factors, the difference of proportion along with its 95% CI were generated from the CMH test, the adjusted factors include HBV DNA level at baseline and the history of oral anti-HBV drug. When the subgroup is one of the random stratification factors, the difference of proportion along with its 95% CI were generated using normal approximate method. | | | | | | |